The U.S. Food and Drug Administration recently approved the drug Amitiza for the treatment of irritable bowel syndrome with constipation in women ages 18 and older.

AMITIZA, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride ...

The Food and Drug Administration approved the first U.S. drug to treat irritable bowel syndrome with constipation in adult women, a medicine marketed by Takeda Pharmaceutical Co and its developer ...

May 1 -- WEDNESDAY, April 30 (HealthDay News) -- Amitiza (lubiprostone) has been approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome accompanied by constipation ...

Invivodata designed and implemented a combination of site-based and field-based ePRO data capture systems to collect efficacy data for Sucampo’s phase 2 and 3 trials of Amitiza for IBS-C treatment.

Amitiza had a market value of approximately $427 million for the 12 months ended Sept. 30, 2020, according to IQVIA. Par launches authorized generic of Amitiza | Drug Store News Skip to main content ...

The FDA has approved Sucampo and Takeda's supplemental New Drug Application for Amitiza to treat opioid-induced constipation in adults with chronic non-cancer pain. Amitiza is already indicated ...

Sucampo Pharmaceuticals Inc. won approval to expand the use of its Amitiza drug to treat opioid-induced constipation in patients with chronic non-cancer pain. The approval spurred the company’s ...

For the majority of drugs, end-of-lifecycle planning usually involves a reining-in of marketing costs. But Sucampo CEO Peter Greenleaf is doing the exact opposite. In the firm’s second-quarter ...

Sucampo and Takeda Pharmaceuticals announced that the FDA has granted priority review of their supplemental new drug application (sNDA) filing for Amitiza (lubiprostone), seeking approval for the ...

Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will ...

ROCKVILLE, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that the U.S. Food and Drug ...